fingolimod hydrochloride has been researched along with Intraepithelial Prostatic Neoplasia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, KW; Chiu, YT; Chua, CW; Ling, MT; Man, K; Wang, X; Wong, YC; Yuen, HF | 1 |
1 other study(ies) available for fingolimod hydrochloride and Intraepithelial Prostatic Neoplasia
| Article | Year |
|---|---|
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Case-Control Studies; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Propylene Glycols; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Sphingosine; Tumor Cells, Cultured | 2009 |